CLINICAL_TRIALS
trial_result
· 2015-03-31
Clinical Trial Update: Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis [Phase 3]
Summary
Phase 3 trial results for isavuconazole (BAL8557) as primary treatment for invasive aspergillosis have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Astellas Pharma Inc | Conditions: Aspergillosis, Invasive Fungal Infection | Phase 3 | Status: COMPLETED | Results posted: 2015-03-31